REGLAN (metoclopramide hydrochloride) by Pfizer is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. First approved in 1983.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
REGLAN (metoclopramide HCl) is a small-molecule dopamine antagonist that enhances upper gastrointestinal motility and prevents nausea/vomiting. It accelerates gastric emptying, increases lower esophageal sphincter pressure, and blocks chemoreceptor trigger zone stimulation. Indicated for gastroesophageal reflux, diabetic gastroparesis, and post-operative nausea.
Mature product nearing loss of exclusivity with minimal Part D claims; team focus is shifting toward cost management and generic transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…
Worked on REGLAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on REGLAN offers limited growth but stable, specialized roles in cost containment, generic transition strategy, and market access—ideal for professionals seeking defensive portfolio management experience. Positions are primarily in operations, compliance, and market access rather than brand-building or innovation.